Agilon Health Q3 revenue beats estimates, raises FY guidance

By Reuters News


Overview

  • U.S. value-based care platform's Q3 revenue rose 6%, beating analyst expectations

  • Net income turned positive in Q3, beating analyst estimates

  • Adjusted EBITDA for Q3 rose, driven by improved pricing and payor contracting


Outlook

  • Company raises 2026 revenue guidance to $5.87 bln-$5.89 bln from $5.78 bln-$5.86 bln

  • Company lifts 2026 adjusted EBITDA outlook to $145 mln-$155 mln from $75 mln-$95 mln

  • Company expects 2026 medical services expense ratio of 90.5%-90.3%, improved from 91.9%-91.4% prior


Result Drivers

  • MEMBERSHIP DECLINE - Co said total members on platform fell 8% YoY due to disciplined contracting, market exits and measured growth approach

  • REVENUE DRIVERS - Revenue rose due to higher-than-expected burden of illness performance, payor contracting, and improved pricing, partly offset by lower membership

  • LOWER MEDICAL COSTS - Medical services expense ratio improved to 88.5% from 104.0%, reflecting favorable claims development


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$1.52 bln

$1.46 bln (14 Analysts)

Q3 Net Income

Beat

$35 mln

-$21.005 mln (9 Analysts)

Q3 Adjusted EBITDA

Beat

$64 mln

$506,690 (13 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy."

  • Wall Street's median 12-month price target for agilon health, inc. is $115.00, about 31% above its November 3 closing price of $87.79


Reuters Recommended Reads

  • Nov 4 - Health insurers, hospitals rally after sweeping midterm win for Democrats

  • Nov 3 - Senior care provider InnovAge's Q1 revenue beats as participants increase

  • Nov 2 - Hinge Health Q3 revenue jumps 52%, beats estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.